12 months from EMA approval, the client wished to understand the revenue optimal ex-US list and net price guidance for Product X, targeting a rare CNS disease with an established SoC.
The goal was to shorten the time to access and revenue generation throughout Europe while achieving a sustainable price.
Do you want to learn more about the successful outcome for this case study? Are you interested in P4A Services or just want to say Hi?
